Key clinical point: Presence and timing of erythema or sclerosis may predict the likelihood of clinical response and survival for patients with chronic graft-vs.-host disease (GVHD).

Major finding: Overall survival was greater in patients with prevalent cases of erythema (HR, 0.29; 95% CI, 0.09-0.87; P = .03).

Study details: A prospective, observational study of 242 patients in the Chronic GVHD Consortium with cutaneous manifestations, between 2007 and 2012.

Disclosures: This study was funded by a career development award from the U.S. Department of Veterans Affairs and grants from the National Institutes of Health/National Cancer Institute.